Alterity Therapeutics Director Awarded 2 Million Options at $1 Exercise Price

Julian Michael Babarczy, a director of Alterity Therapeutics Ltd (ATHE), was awarded 2 million unlisted options on June 15, 2026, with an exercise price of $1.00 per share. The options expire on June 15, 2031. This represents a derivative transaction where the director acquired the right to purchase ordinary shares in the future. The options were granted at no cost to the director (transaction price of $0), and following this award, the director holds 2 million options. The filing indicates these are held indirectly through Vaucluse Investment Holdings Pty Ltd (Jigsaw Investment A/C). The transaction was reported timely on June 23, 2026, and is subject to Section 16 reporting requirements.